The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2024 | Exploring gaps in neuroendocrine carcinoma understanding
Lorraine A. Chantrill, PhD, Wollongong Hospital, New South Wales, Australia, addresses significant gaps in understanding neuroendocrine carcinomas. Key questions include whether these cancers initiate as high-grade tumors or evolve from more benign subtypes. Investigating intratumoral heterogeneity and potential less active cell populations is crucial. The existence of heterogeneity between tumors within the same patient remains unexplored. Prof. Chantrill emphasizes the need to analyze different tumors within a patient for a comprehensive understanding. Additionally, she highlights the challenging patient experience due to the poor prognosis and limited treatment options, especially after initial treatments fail. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
